Search

everythinglearnresearchcommunity

for

Search:↓

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.

2 Deoxy D Ribose may promote hair growth and aid wound healing, potentially enhancing microneedling effects. Users discuss its combination with microneedling for better hair growth results.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

A user is considering a hair transplant and seeks advice on choosing a clinic, mentioning Spain, Turkey, and the U.S. as options. They are inspired by FC Barcelona goalkeeper ter Stegen's results and are willing to spend up to 50k euros for the best outcome.

The user experienced hair regrowth with dutasteride but later lost progress despite using minoxidil foam and dermastamping. Suggestions included reducing dermastamping frequency, conducting blood tests, and considering oral minoxidil or different brands of dutasteride.

The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

A user shared their 4-month progress using 2.5mg minoxidil, 1mg finasteride, and 10mg biotin, noting slight testicular discomfort initially but no significant hairline changes yet. Another user reported similar treatment results, with hair darkening at the scalp center and small temple hairs.

17M approaching Norwood 2, using topical minoxidil and considering finasteride, oral minoxidil, and pyrilutamide. Plans to study dermatology and possibly get a hair transplant at 25 if treatments don't work.

User celebrates 2-year anniversary of 2500 FUE hair transplant procedure and worries about future hair loss. Others compliment the results and suggest using Dut and Min to maintain hair.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The user is questioning whether their hair shows signs of regrowth or just normal growth after two weeks. They are using Minoxidil, Finasteride, and RU58841 for hair treatment.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

A 31-year-old man shared his 2-year experience using finasteride and minoxidil after a hair transplant on the front and mid scalp, noting improvement but still having a thin crown. He recently started dermastamping, plans to use ketoconazole shampoo, and uses hair fibers for extra confidence at events.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The user shared their 2-year progress using finasteride and minoxidil, with significant improvement after adding dutasteride in the last year. They advise persistence with the treatment despite initial setbacks.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

User discovered hair fibers, tried Toppik but concerned about ingredients. Considering Boldify (cotton-based, cheaper) and Surethik (keratin-based) as better options.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.